NY-ESO-1 expression in sarcomas
Open Access
- 4 November 2012
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 1 (8) , 1409-1410
Abstract
NY-ESO-1 (CTAG 1B) is highly expressed in the majority of synovial sarcomas and myxoid/round cell liposarcomas as well as in a subset of melanomas, but only rarely in other mesenchymal tumors. This...Keywords
This publication has 9 references indexed in Scilit:
- NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosisLaboratory Investigation, 2012
- NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcomaCancer, 2012
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1Journal of Clinical Oncology, 2011
- Myxoid/round cell and pleomorphic liposarcomasCancer, 2007
- Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny-eso-1 but not mage-a1 or ct7International Journal of Cancer, 2001
- Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomasBritish Journal of Cancer, 2001
- Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR MoleculesThe Journal of Immunology, 2000
- Cancer immunotherapy in clinical oncologyCancer Chemotherapy and Pharmacology, 2000
- A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screeningProceedings of the National Academy of Sciences, 1997